These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9807519)

  • 41. Treatment and prevention of obesity--are there critical periods for intervention?
    Lawlor DA; Chaturvedi N
    Int J Epidemiol; 2006 Feb; 35(1):3-9. PubMed ID: 16396899
    [No Abstract]   [Full Text] [Related]  

  • 42. [Epidemiology and prevention of cardiovascular diseases].
    Jánosi A
    Orv Hetil; 2005 Apr; 146(15):683-8. PubMed ID: 15895792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
    Waltering A; Hemkens L; Florack C
    Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Primary prevention of cardiovascular disease in nursing practice: focus on children and youth: a scientific statement from the American Heart Association Committee on Atherosclerosis, Hypertension, and Obesity in Youth of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity, and Metabolism.
    Hayman LL; Meininger JC; Daniels SR; McCrindle BW; Helden L; Ross J; Dennison BA; Steinberger J; Williams CL; ; ; ;
    Circulation; 2007 Jul; 116(3):344-57. PubMed ID: 17592077
    [No Abstract]   [Full Text] [Related]  

  • 45. Aspirin for the primary prevention of adverse cardiovascular events.
    Estes K; Thomure J
    Crit Care Nurs Q; 2008; 31(4):324-39. PubMed ID: 18815480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
    Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B
    Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progress in prevention: should we screen for risk factors or disease? A current debate in the prevention of cardiovascular events.
    Dennison CR; Hughes S
    J Cardiovasc Nurs; 2009; 24(1):18-20. PubMed ID: 19114796
    [No Abstract]   [Full Text] [Related]  

  • 48. Benefit/risk ratio of statins in primary prevention.
    Reidenberg MM
    Clin Pharmacol Ther; 2008 Mar; 83(3):498-500. PubMed ID: 17538549
    [No Abstract]   [Full Text] [Related]  

  • 49. [Proper role. Impossible mission].
    Magnon R
    Rev Infirm; 1990 Sep; 40(14):34-7. PubMed ID: 2244117
    [No Abstract]   [Full Text] [Related]  

  • 50. What type of exercise prevents cardiovascular disease in postmenopausal women?
    Rivet C
    CMAJ; 2003 Feb; 168(3):314. PubMed ID: 12566338
    [No Abstract]   [Full Text] [Related]  

  • 51. Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease.
    Gotto AM
    Circulation; 2006 Sep; 114(12):1310-4; discussion 1314. PubMed ID: 16982952
    [No Abstract]   [Full Text] [Related]  

  • 52. Progress in prevention: preventing cardiovascular disease: a global challenge and a call to action.
    Hayman LL; Hughes S
    J Cardiovasc Nurs; 2008; 23(1):65-6. PubMed ID: 18158511
    [No Abstract]   [Full Text] [Related]  

  • 53. What nurses stand for.
    Gordon S
    Colo Nurse; 1997 Sep; 97(3):27-9. PubMed ID: 9355328
    [No Abstract]   [Full Text] [Related]  

  • 54. Limitations of current cardiovascular disease risk assessment strategies in women.
    Sibley C; Blumenthal RS; Merz CN; Mosca L
    J Womens Health (Larchmt); 2006; 15(1):54-6. PubMed ID: 16417419
    [No Abstract]   [Full Text] [Related]  

  • 55. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipid lowering strategies.
    Morrell J
    Indian Heart J; 1999; 51(5):489-93. PubMed ID: 10721637
    [No Abstract]   [Full Text] [Related]  

  • 57. GPs' views of absolute cardiovascular risk and its role in primary prevention.
    Torley D; Zwar N; Comino EJ; Harris M
    Aust Fam Physician; 2005 Jun; 34(6):503-4, 507. PubMed ID: 15931411
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primordial prevention of cardiovascular disease through applied genetics.
    Williams RR; Hopkins PN; Stephenson S; Wu L; Hunt SC
    Prev Med; 1999 Dec; 29(6 Pt 2):S41-9. PubMed ID: 10641817
    [TBL] [Abstract][Full Text] [Related]  

  • 59. JUPITER study highlights C-reactive protein as a cardiac risk factor.
    Cardiovasc J Afr; 2009; 20(2):146. PubMed ID: 19421655
    [No Abstract]   [Full Text] [Related]  

  • 60. Reports from the Swedish Council on Technology Assessment in Health Care (SBU).
    Int J Technol Assess Health Care; 1999; 15(2):424-36. PubMed ID: 10507199
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.